Login to Your Account



Biopharm America

Dress for Success: Panel Mulls Best Early Stage Deal Chances

By Randy Osborne
Staff Writer

Wednesday, September 18, 2013
us_resized.jpg

BOSTON – Even with a solid strategic fit, quality assets on the table and the likelihood of reimbursement by payers, intellectual property (IP) glitches can hurt a deal, warned Sanjeev Munshi, director of worldwide licensing and acquisition for Merck & Co. Inc.

Munshi’s remarks came during a panel talk called “How to Position Your Early Stage Company for Success” at Biopharm America, a three-day event focused on partnering.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription